2025-10-24 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co. (LLY) based on the information provided.

## Eli Lilly and Co. (LLY) Stock Analysis

**Ticker:** LLY
**Company Description:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

*   **LLY Cumulative Return:** 202.14%
*   **VOO Cumulative Return:** 99.09%
*   **Absolute Divergence:** 109.8
*   **Relative Divergence:** 50.8 (This indicates LLY is currently positioned in the upper half of its historical divergence range relative to the S&P 500.)

**Analysis:** LLY has significantly outperformed the S&P 500. The relative divergence suggests the current outperformance is substantial compared to its historical range.

### 2. Alpha, Beta Analysis

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2015-2017  | 8.0%    | 72.9%   | -21.0%  | -0.0  | 77.8   |
| 2016-2018  | 43.0%   | 68.9%   | 27.0%   | -0.1  | 106.5  |
| 2017-2019  | 42.0%   | 68.9%   | 20.0%   | 0.1   | 121.0  |
| 2018-2020  | 34.0%   | 79.6%   | 11.0%   | 0.2   | 155.4  |
| 2019-2021  | 53.0%   | 79.6%   | 7.0%    | 0.6   | 254.3  |
| 2020-2022  | 64.0%   | 79.6%   | 64.0%   | 0.5   | 336.8  |
| 2021-2023  | 124.0%  | 78.9%   | 123.0%  | 0.2   | 536.6  |
| 2022-2024  | 132.0%  | 81.1%   | 112.0%  | 0.2   | 710.6  |
| 2023-2025  | 96.0%   | 83.4%   | 33.0%   | 0.2   | 736.0  |

**Analysis:**

*   **CAGR:**  Shows strong growth over various periods, particularly in recent years.
*   **MDD:**  Maximum Drawdown is significant, indicating potential volatility and risk.
*   **Alpha:**  Generally positive and increasing, indicating LLY's returns are increasingly independent of the market. The very high Alpha in recent periods (2020-2025) stands out.
*   **Beta:**  Low Beta values suggest LLY is less sensitive to overall market movements.
*   **Cap(B):**  Shows the increasing capitalization of the company.

### 3. Recent Price Action

*   **Last Price:** 799.57
*   **Last Market Data:** Price: 821.04, Previous Close: 812.43, Change: 1.06 (Indicates a slight positive change in the last trading session)
*   **5-day MA:** 811.46
*   **20-day MA:** 802.42
*   **60-day MA:** 751.42

**Analysis:** The price is currently below the 5-day and 20-day moving averages but above the 60-day moving average. The recent market data showing an increase of 1.06 suggests a positive move.

### 4. Technical Indicators & Expected Return

*   **MRI (Market Risk Indicator):** 0.9 (Medium Investment Recommended)
*   **RSI:** 39.33 (Approaching oversold territory)
*   **PPO:** -0.60 (Negative, suggesting a slight downtrend)
*   **Hybrid Signal:** "cash\_0% Buy 100% of cash"  (Strong Buy signal based on the hybrid model)
*   **Delta_Previous_Relative_Divergence:** -5.8 (Negative, indicating recent underperformance relative to the comparison benchmark)
*   **Expected Return:** 129.4% (Significant long-term outperformance expectation)

**Analysis:**

*   The MRI suggests a medium investment recommendation.
*   The RSI is approaching oversold territory, which could indicate a potential buying opportunity.
*   The PPO indicates a possible short-term downtrend.
*   The negative Delta\_Previous\_Relative\_Divergence confirms recent underperformance, possibly related to profit-taking or market corrections.
*   The very high expected return suggests strong confidence in LLY's long-term growth potential.
*   The market data showing an increase of 1.06 could be considered a slight rebound from any short-term declines.

### 5. Recent News & Significant Events

*   **Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies:**  Positive news, potentially impacting the valuation of companies in the obesity treatment space.
*   **Radiopharmaceuticals Market to Reach US$ 13.4 Billion by 2033:**  Indicates growth potential in a related pharmaceutical segment.
*   **Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock?**:  This news suggests positive recent momentum and invites a discussion on whether to maintain, increase, or decrease positions.
*   **Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?**: This highlights the importance of earnings growth as a driver of stock value.
*   **How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?:** Important as a comparison, this evaluates the competitive landscape of the company.
*   **Novo Nordisk’s new ‘king’ tightens his grip at obesity drug giant:**  Suggests increased competition in the obesity drug market, which could impact LLY.

**Impact:** The news is generally positive, with a potential concern about increased competition in the obesity drug market.

### 6. Analyst Opinions

*   **Consensus:** Buy (~1.76)
*   **Target Price (avg/high/low):** 898.04 / 1190.00 / 650.00

**Analysis:** The analyst consensus is "Buy" with a significant upside potential based on the average and high target prices.

### 7. Recent Earnings Analysis

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-08-07 | 6.30 | 15.56 B$   |
| 2025-05-01 | 3.07 | 12.73 B$   |
| 2024-10-30 | 1.08 | 11.44 B$   |
| 2024-08-08 | 3.29 | 11.30 B$   |
| 2025-08-07 | 3.29 | 11.30 B$   |

**Analysis:** The most recent EPS and revenue figures show strong growth compared to previous periods.

### 8. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-06-30   | $15.56B     | 84.27%        |
| 2025-03-31   | $12.73B     | 82.53%        |
| 2024-12-31   | $13.53B     | 82.24%        |
| 2024-09-30   | $11.44B     | 81.02%        |
| 2024-06-30   | $11.30B     | 80.80%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE       |
|--------------|-------------|-----------|
| 2025-06-30   | $18.27B     | 30.98%    |
| 2025-03-31   | $15.76B     | 17.50%    |
| 2024-12-31   | $14.19B     | 31.07%    |
| 2024-09-30   | $14.24B     | 6.81%     |
| 2024-06-30   | $13.56B     | 21.88%    |

**Analysis:**  Revenue and profit margins are increasing, reflecting strong business performance. The high and increasing ROE indicates efficient use of equity to generate profits.

### 9. 종합 Conclusion

Eli Lilly and Co. (LLY) shows strong fundamentals and positive momentum. The company has significantly outperformed the S&P 500, with analysts projecting further upside. Recent news is predominantly positive, particularly related to obesity studies. The strong earnings and high ROE confirm solid financial health. While the stock may be experiencing some short-term pullback (indicated by the RSI, PPO, and recent divergence change), the overall outlook remains positive, especially for long-term investors. However, increased competition in the obesity drug market warrants monitoring. The hybrid signal and MRI suggests a safe investment.
